Precigen, INC 8-K filings

Precigen announced robust second quarter 2026 financial results, highlighted by significant revenue growth from PAPZIMEOS and a notable shift to profitability.

Precigen stockholders approved an amendment to the 2023 Omnibus Incentive Plan to increase available shares by 7 million at the 2026 Annual Meeting.

Precigen announced strong first quarter 2026 financial results, driven by the successful launch of PAPZIMEOS, with net product revenue reaching $21.6 million and operations projected to reach cash flow break-even by year-end.

Precigen announced full year 2025 financial results, highlighting the successful US launch of PAPZIMEOS and a strategic path to cash flow break-even by the end of 2026.

Precigen, Inc. announced its third quarter 2025 financial results, highlighting the successful commercial launch of PAPZIMEOS for recurrent respiratory papillomatosis and a strengthened cash position despite a significant net loss increase driven by non-cash items.

Precigen, Inc. announced the conversion of $79 million in Series A Convertible Perpetual Preferred Stock into over 54.9 million shares of common stock.

Precigen, Inc. announced a new senior secured term loan facility of up to $125 million from Pharmakon Advisors, LP, with $100 million funded immediately to bolster its balance sheet and support PAPZIMEOS commercialization.

Precigen, Inc. has entered into a multi-year exclusive commercial supply agreement with Catalent Maryland, Inc. for the fill and finish manufacturing of its PRGN-2012 product.

Precigen, Inc. announced the U.S. FDA approval of PAPZIMEOS (zopapogene imadenovec-drba), the first and only approved therapy for adults with recurrent respiratory papillomatosis (RRP).

Precigen, Inc. stockholders approved a significant increase in authorized common stock, expansion of incentive plans, and the issuance of PIK dividends to a key investor at their 2025 Annual Meeting.

Precigen reports its Q1 2025 financial results, highlighting progress with PRGN-2012, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), and anticipates a commercial launch in 2025.

Precigen announces its full year 2024 financial results, highlighting FDA priority review for PRGN-2012 and extending its cash runway into 2026.

Precigen Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price rule after its common stock price remained above $1.00 for 10 consecutive business days.

Precigen has successfully completed a $79 million private placement and submitted a Biologics License Application (BLA) to the FDA for PRGN-2012, a potential treatment for recurrent respiratory papillomatosis.

Precigen, Inc. has completed the sale of assets related to its former collaboration on the FCX-007 product candidate to an affiliate of Paragon Biosciences, LLC for $8.5 million.

Precigen reports progress on its lead candidate PRGN-2012, including alignment with the FDA for a BLA submission, while also detailing its third quarter 2024 financial results.

Precigen, Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1, putting the company at risk of delisting.

Precigen, Inc. has terminated its Amended and Restated License Agreement with Alaunos Therapeutics, Inc., regaining all rights to its previously licensed technology.

Precigen Inc. has announced the departure of Jeffrey Perez, Senior Vice President of Intellectual Property Affairs, effective November 1, 2024.

Precigen has granted performance stock units to key executives, vesting upon the achievement of FDA submission and approval milestones for their PRGN-2012 investigational product.

Precigen announced a strategic reprioritization to focus on its PRGN-2012 gene therapy program for RRP, alongside a $31.4 million capital raise.

Precigen, Inc. has successfully entered into an underwriting agreement for a public offering of its common stock, expected to yield net proceeds of approximately $31.4 million.

Precigen is strategically focusing on its PRGN-2012 gene therapy program, initiating a public offering to raise $30 million, and streamlining operations.

Precigen's stockholders approved an amendment to the 2023 Omnibus Incentive Plan, increasing the share pool by 2 million, and elected Nancy Howell Agee to the Board at their annual meeting on July 5, 2024.

Precigen reported its first quarter 2024 financial results and provided updates on its clinical programs, including the anticipated presentation of pivotal Phase 2 data for PRGN-2012 at the ASCO Annual Meeting.

Precigen reports its full year 2023 financial results and provides a business update, highlighting progress in its clinical programs and plans for a BLA submission for PRGN-2012 in the second half of 2024.

Precigen Inc. has entered into continuing employment agreements with its Chief Financial Officer and Chief Operating Officer, providing severance benefits upon certain terminations.